Skip to main content
SpringerLink
Log in

Gout, Hyperuricemia, and Parkinson’s Disease: A Protective Effect?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Oxidative stress is potentially involved in the pathogenesis of Parkinson’s disease (PD). Serum uric acid, because of its antioxidant effect, might prevent the development of this neurodegenerative disorder. Indeed, a number of epidemiologic studies have consistently reported a strong inverse association between serum uric acid and the risk of PD. The risk of PD is also lower among individuals with gout. In addition, suggestive evidence from clinical studies shows high levels of uric acid as a marker of better prognosis in PD. Future research should determine the mechanisms underlying this association. This, in turn, could be used in the development of new preventive strategies and treatments for PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently have been highlighted as: • Of importance •• Of major importance

  1. Gabriel SE, Michaud K: Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009, 11:229.

    Article  PubMed  Google Scholar 

  2. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811–1821.

    Article  CAS  PubMed  Google Scholar 

  3. Hirtz D, Thurman DJ, Gwinn-Hardy K, et al.: How common are the “common” neurologic disorders? Neurology 2007, 68:326–337.

    Article  CAS  PubMed  Google Scholar 

  4. • Elbaz A, Moisan F: Update in the epidemiology of Parkinson’s disease. Curr Opin Neurol 2008, 21:454–460. This article provides an excellent review of the most recent findings on the epidemiology of PD.

  5. Savitt JM, Dawson VL, Dawson TM: Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006, 116:1744–1754.

    Article  CAS  PubMed  Google Scholar 

  6. Larumbe Ilundáin R, Ferrer Valls JV, Viñes Rueda JJ, et al.: Case-control study of oxidative stress and plasma iron metabolism markers in Parkinson’s disease [in Spanish]. Rev Esp Salud Publica 2001, 75:43–53.

  7. Annanmaki T, Muuronen A, Murros K: Low plasma uric acid level in Parkinson’s disease. Mov Disord 2007, 22:1133–1137.

    Article  PubMed  Google Scholar 

  8. Andreadou E, Nikolau C, Gournaras F, et al.: Serum uric acid levels in patients with Parkinson’s disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 2009, 111:724–728.

    Article  PubMed  Google Scholar 

  9. Ahlskog JE, Uitti RJ, Low PA, et al.: No evidence for systemic oxidant stress in Parkinson’s or Alzheimer’s disease. Mov Disord 1995, 10:566–573.

    Article  CAS  PubMed  Google Scholar 

  10. Davis JW, Grandinetti A, Waslien CI, et al.: Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol 1996, 144:480–484.

    CAS  PubMed  Google Scholar 

  11. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM: Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005, 58:797–800.

    Article  PubMed  Google Scholar 

  12. •• Weisskopf MG, O’Reilly E, Chen H, et al.: Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 2007, 166:561–567. This article provides results on the association of serum uric acid with the incidence of PD and, more importantly, meta-analyses results from prospective studies addressing this association.

  13. • Chen H, Mosley TH, Alonso A, Huang X: Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2009, 169:1064–1069. The article analyzes the association of serum uric acid with PD in a cohort including both Caucasians and African Americans.

  14. Gao X, Chen H, Choi HK, et al.: Diet, urate, and Parkinson’s disease risk in men. Am J Epidemiol 2008, 167:831–838.

    Article  PubMed  Google Scholar 

  15. •• Alonso A, García Rodríguez LA, Logroscino G, Hernán MA: Gout and risk of Parkinson disease: a prospective study. Neurology 2007, 69:1696–1700. This is the first published report of an inverse association between gout and risk of PD. The authors used data from a large computerized database.

  16. • de Vera M, Rahman MM, Rankin J, et al.: Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Rheum 2008, 59:1549–1554. This article provides results from an analysis that confirmed previous observations on the inverse association of gout with PD risk in a larger population.

  17. Zhang W, Doherty M, Bardin T, et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.

    Article  CAS  PubMed  Google Scholar 

  18. •• Schwarzschild MA, Schwid SR, Marek K, et al.: Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008, 65:716-723. This article provides secondary analysis of a clinical trial in patients with early PD, showing that serum uric acid is a strong predictor of disease and slower progression.

  19. • Ascherio A, LeWitt PA, Xu K, et al.: Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009, 66:1460–1468. This article provides another analysis from a clinical trial in early PD that confirms the value of uric acid as a predictor of clinical progression in PD.

  20. Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K: Uric acid associated with cognition in Parkinson’s disease. Parkinsonism Relat Disord 2008, 14:576–578.

    Article  PubMed  Google Scholar 

  21. Dehghan A, Köttgen A, Yang Q, et al.: Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008, 372:1953–1961.

    Article  CAS  PubMed  Google Scholar 

  22. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans agains oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858–6862.

    Article  CAS  PubMed  Google Scholar 

  23. Duan W, Ladenheim B, Cutler RG, et al: Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 2002, 80:101–110.

    Article  CAS  PubMed  Google Scholar 

  24. Spitsin S, Hooper DC, Leist T, et al.: Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 2001, 7:313–319.

    CAS  PubMed  Google Scholar 

  25. Scott GS, Spitsin SV, Kean RB, et al.: Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 2002, 99:16303–16308.

    Article  CAS  PubMed  Google Scholar 

  26. Shen H, Chen GJ, Harvey BK, et al.: Inosine reduces ischemic brain injury in rats. Stroke 2005, 36:654–659. (Published erratum appears in Stroke 2005, 36:1106.)

    Google Scholar 

  27. Irizarry MC, Raman R, Schwarzschild MA, et al.: Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 2009, 6:23–28.

    Article  CAS  PubMed  Google Scholar 

  28. Euser SM, Hofman A, Westendorp RG, Breteler MM: Serum uric acid and cognitive function and dementia. Brain 2009, 132:377–382.

    Article  CAS  PubMed  Google Scholar 

  29. Markowitz CE, Spitsin S, Zimmerman V, et al.: The treatment of multiple sclerosis with inosine. J Altern Complement Med 2009, 15:619–625.

    Article  PubMed  Google Scholar 

Download references

Disclosures

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 1300 South 2nd Street, Suite 300, Minneapolis, MN, 55454, USA

    Alvaro Alonso & Kelly A. Sovell

Authors
  1. Alvaro Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly A. Sovell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alvaro Alonso.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alonso, A., Sovell, K.A. Gout, Hyperuricemia, and Parkinson’s Disease: A Protective Effect?. Curr Rheumatol Rep 12, 149–155 (2010). https://doi.org/10.1007/s11926-010-0083-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-010-0083-4

Keywords

Search

Navigation